Sanofi announced the discontinuation of clinical development for amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis. The company decided not to submit the drug for global regulatory reviews because the current efficacy and safety evidence does not suggest it would provide a meaningful improvement over existing standards of care. Sanofi is not amending its full-year 2026 guidance due to this decision. Additionally, the company is evolving its Executive Committee effective September 1, 2026, to support its next strategic chapter. Sanofi is a biopharma company that develops medicines and vaccines.

The US Food and Drug Administration (FDA) approved subcutaneous Sarclisa Escena for the treatment of patients with multiple myeloma (MM) across all existing intravenous indications. This marks the first anticancer treatment approved for administration via an on-body injector (OBI) using Enable Injections' CirCLIQ device. The approval follows the phase 3 IRAKLIA study, which demonstrated non-inferiority in efficacy, pharmacokinetics, and safety compared to intravenous administration. The subcutaneous formulation offers a more convenient administration experience for patients and reduces the physical burden on healthcare providers. Sanofi is a biopharma company that develops medicines and vaccines.

Sanofi's Nexviazyme met all primary and secondary endpoints in a phase 3 study for infantile-onset Pompe disease. Sanofi is a global healthcare company specializing in pharmaceutical research and development.

Sanofi announced several regulatory approvals and a key leadership appointment in June 2026. Japan approved the subcutaneous formulation of Sarclisa for multiple myeloma patients, and Wayrilz was also approved in Japan for treating immune thrombocytopenia. In the EU, Cenrifki (tolebrutinib) received approval as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses. Additionally, Paulo Fontoura was appointed as the company's Global Head of R&D. Sanofi is a pharmaceutical company that develops and manufactures medicines.

On June 13, 2026, Sanofi announced that the U.S. regulatory authorities approved Tzield as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes. Sanofi is a pharmaceutical company that develops and manufactures medicines and vaccines.

Sanofi announced three key developments in June 2026. The company launched its 2026 global employee stock purchase plan on June 4. On June 8, the EU approved Sarclisa subcutaneous as the first anticancer treatment administered via an on-body injector. On June 10, the company provided an update on the MOBILIZE phase 3 study of riliprubart for chronic inflammatory demyelinating polyneuropathy. Sanofi is a pharmaceutical company that develops and manufactures vaccines, specialty care, and general medicines.